The Peptide & GLP-1 Desk

We will not tell you what to take. We will tell you what you are being sold.

This is the most aggressively marketed corner of consumer health, and nearly every source covering it is paid by someone who sells or prescribes these compounds. We are not. What follows is structural literacy: the categories, the process, and the claim patterns. We work that way because that knowledge does not expire the way a status update does.

First, place what you are looking at

Four categories, and the difference between them is everything

Almost every bad outcome in this market starts with someone believing they are buying something from one category when they are buying from another.

FDA-approved drug

Reviewed for safety and efficacy for a specific use, made under manufacturing regulation.

Standard medical risk

What it means

The manufacturer submitted clinical trial evidence, the agency reviewed it, and the product is approved for named indications. Manufacturing is subject to inspection. The dose in the vial is the dose on the label, and adverse events are tracked systematically after approval.

Who oversees it

FDA pre-market review, ongoing manufacturing inspection, and post-market safety surveillance.

Questions worth asking

Is this the brand-name product, dispensed by a licensed pharmacy?
Am I being prescribed it for an approved indication, or off-label? If off-label, on what basis?
What does it cost through the manufacturer's own direct-pay programme versus this seller?

Compounded preparation

Mixed by a pharmacy for an individual patient. Not FDA-approved, and not reviewed for safety or efficacy.

Elevated, variable by pharmacy

What it means

Compounding pharmacies prepare medications tailored to an individual patient, historically for genuine clinical needs such as an allergy to an excipient or a strength not commercially made. A compounded product has not been through FDA review. It is legal in defined circumstances, but it is not an approved drug, and the potency and sterility depend on that specific pharmacy's practices.

Who oversees it

Primarily state boards of pharmacy, with federal oversight of larger outsourcing facilities. Oversight is meaningfully lighter than for approved drugs.

Questions worth asking

Is this pharmacy licensed in my state, and can I verify that with the state board directly?
Why am I being given a compounded version rather than the approved drug? Is there a documented clinical reason specific to me?
Has anyone told me this is 'the same as' the brand-name drug? Regulators have treated that specific claim as a violation.
What independent testing confirms potency and sterility for this batch?

"Research use only" chemical

Sold with a label saying it is not for human consumption, by a vendor with no pharmacy licence.

Unquantifiable

What it means

These are sold online with disclaimers stating they are for laboratory research and not for human use. In practice the marketing, the packaging, and the accompanying materials are frequently aimed at people who intend to inject them. The disclaimer is widely misunderstood as a legal or safety assurance. It is neither; regulators assess the intended use of a product from the whole marketing context, not from the disclaimer text.

Who oversees it

Effectively nobody, on the consumer's behalf. No pharmacy licensure, no required purity standard, no adverse event reporting, and no recourse if the vial contains something other than what the label says.

Questions worth asking

Who verified what is actually in this vial, and would that document survive independent scrutiny?
If this causes harm, who is accountable, and under what jurisdiction?
Will this vendor still exist in six months? Enforcement actions have closed a number of the largest ones.
Why is a product allegedly for laboratory research being sold to me with injection supplies?

Investigational compound

Still in clinical trials. No approved version exists at any dose, for anyone, anywhere.

Unquantifiable

What it means

The compound is under study and its trial results may look impressive in press coverage. But the full safety profile is by definition not yet established. That is what the remaining trials are for. Anything sold to consumers under such a name today did not come from the company running those trials.

Who oversees it

The trials themselves are regulated. Consumer sales bearing these names are outside that system entirely.

Questions worth asking

If no approved version exists, where did this material actually come from?
What is known about long-term safety, and what is simply not known yet?
Is the impressive number I read about from a trial of the real compound, and does that tell me anything about what is in this vial?

The single most misread thing in this market

A recommendation is not a rule, and a rule is not availability

Regulatory news gets compressed into “it's legal now” within about forty-eight hours, usually by someone with inventory. Here is the actual sequence.

1
An advisory committee votes
Advisory committees make recommendations. The recommendations are not binding, the agency is not obliged to follow them, and agency staff sometimes recommend the opposite of what the committee votes for.
Nothing has changed yet
2
The agency proposes a rule
A proposal opens a public comment period. Nothing has changed in law yet, and proposals are modified or dropped.
Nothing has changed yet
3
A final rule is published with an effective date
This is the point at which the legal position actually changes, and only in the specific way the rule describes, on the date it specifies.
Legal position has moved
4
A licensed pharmacy can lawfully dispense it to you
Even after a rule takes effect, supply chains, state licensure, and pharmacy practice have to catch up. The gap between 'legally permitted' and 'actually available from a legitimate source' is routinely months.
Legal position has moved

Claim patterns

Six things a seller says when they are over-reaching

You do not need to evaluate the pharmacology to spot these. They are claims about regulation and equivalence, and they are checkable.

"Same as" or "generic version of" a brand-name drug

A compounded preparation is not a generic. Generics are approved after demonstrating equivalence; compounded products are not. Regulators have treated equivalence claims as a specific category of violation.

"FDA approved" applied to a compounded product

Compounded preparations are not FDA-approved by definition. If a seller says otherwise, that is not a wording slip; it is the central thing they are getting wrong.

"Now legal" following a committee vote or news story

Recommendations are not rules. This claim reliably appears within days of any regulatory news and is almost always premature.

"Research use only" alongside dosing charts or injection supplies

The disclaimer and the sales context contradict each other. Regulators read the whole context, and so should you.

A dosing protocol offered before any clinical evaluation

A dose recommended by someone who has not evaluated you, from an entity that profits from the sale, is a sales figure rather than a clinical one.

Before-and-after photographs paired with a purchase link

This specific combination (outcome claim plus immediate purchase path) is the pattern regulators cite most often in enforcement letters.

On testing

What bloodwork can and cannot tell you here

People starting GLP-1 therapy often ask what is worth measuring. We do not recommend protocols, and what to test is a decision for you and a clinician who knows your history. What we can usefully say is which measurements exist and what each one is actually sensitive to.

Rapid weight loss moves several markers on its own

Uric acid, liver enzymes, and lipid values all shift during rapid weight loss independently of any underlying change in disease risk. A result that looks alarming mid-course may be reflecting the rate of loss rather than a new problem.

Uric Acid Alanine Aminotransferase Triglycerides

Lean mass is not visible on a scale or a standard panel

Weight loss includes lean tissue as well as fat. No routine blood marker measures this well. Body composition assessment answers the question that bloodwork cannot, which is worth knowing before paying for a panel that implies otherwise.

Nutrient status can drift when intake falls sharply

Sustained reduced intake is a plausible route to nutrient shortfalls over months. This is a reason for clinical follow-up rather than a reason to buy a supplement stack pre-emptively.

Ferritin Vitamin B12 Vitamin D, 25-Hydroxy

The Mirror Brief

One email when a reference range changes, a panel claim is corrected, or a regulatory status actually moves, not when something is merely proposed. No sponsors from any company we rate.

Unsubscribe anytime. We never sell or share your address.